Dextenza Reduces Ocular Itching Associated with Allergic Conjunctivitis
Dextenza demonstrated a statistically significant mean change in ocular itching in patients with allergic conjunctivitis, according to a press release.
In a Phase 3 clinical trial, 96 patients with seasonal and perennial allergens treated with Dextenza experienced a statistically significant (P < 0.0001) change in ocular itching at 8 at 3 minutes, 5 minutes, and 7 minutes post challenge compared to baseline.
“Approximately 10-15% of my allergic conjunctivitis patients are not adequately controlled with current therapy and thus require use of topical steroids. This patient group comprises commonplace seasonal and perennial allergic conjunctivitis as well as more severe atopic and vernal keratoconjunctivitis,” said Ken Kenyon, MD, an investigator in the Dextenza trial and Clinical Professor of Ophthalmology at Tufts / New England Eye Center, in the press release. “Having a potent and effective anti-inflammatory medication to personally administer in the office setting without concern for patient compliance or potential misuse would be a great addition to my therapeutic toolbox.”
Read the full press release here.